Search results
Neurocrine Biosciences to Present Phase 3 Baseline Characteristics Data from the CAHtalyst™ Program...
WDTN-TV 2 Dayton· 11 hours agoNeurocrine Biosciences, Inc. (Nasdaq: NBIX) today announced that it will present key information from its neuroendocrinology pipeline, including baseline characteristics data from its CAHtalyst ...
NIH Reports Researchers Review Findings and Clinical Messages from the Women’s Health Initiative 30...
Sierra Sun Times· 1 day agoData from influential study underscore the importance of personalized and shared decision-making to...
Harvard Doctor Says This Much Omega 3 per Day Is Essential for Good Health — Here’s How To Get It
Woman's World via Yahoo News· 7 days agoFor more vitamins and nutrients that can boost your health: This content is not a substitute for...
‘Some of us want to dance to the finish line’: Controversial pellet therapy battling symptoms of...
WSMV Nashville· 4 days agoRunning used to be Jamie Neumayer’s passion until the symptoms of menopause started running over...
10 New And Inspiring Innovations For Women’s Health
Forbes· 6 days agoLast week the Women’s Health Innovation Summit (WHIS) Europe, took place in Basel, Switzerland. WHIS is first and foremost a networking event where...
Neurocrine Biosciences Presented CAHtalyst™ Pediatric Study Baseline Characteristics and CAHtalog™...
WKBN 27 Youngstown· 4 days agoBaseline characteristics of the subjects who enrolled in the CAHtalyst Pediatric Phase 3 study were presented (Poster# 56).
New Advanced Infusion Center location looks to 'help the community'
Appeal-Democrat, Marysville, Calif. via Yahoo News· 5 days agoMay 2—Advanced Infusion Center celebrated the grand opening of its new location in Yuba City last week. The center is a physician-owned outpatient center that offers the administration of different ...
Study Explores Controversial Hormone Therapy for Menopause—With Surprising Results
Prevention via Yahoo News· 6 days agoFor prevention, “we do know that estrogen therapy is protective against developing osteoporosis,”...
Amgen Inc (AMGN) Q1 2024 Earnings: Aligns with EPS Projections Amid Revenue Growth and Challenges
GuruFocus.com via Yahoo Finance· 5 days agoCompany Overview Amgen is a pioneering biotechnology firm, renowned for its innovative human therapeutics. With a diverse portfolio that includes treatments for cancer, heart ...
Q2 2024 EPS Estimates for Amgen Inc. Reduced by Leerink Partnrs (NASDAQ:AMGN)
ETF DAILY NEWS· 21 hours agoAmgen Inc. (NASDAQ:AMGN – Free Report) – Stock analysts at Leerink Partnrs reduced their Q2 2024 earnings estimates for Amgen in a research report issued on Friday, May 3rd. Leerink Partnrs ...